Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherBasic Science Investigations

18F-Fluoroerythronitroimidazole Radiation Dosimetry in Cancer Studies

Tuula Tolvanen, Kaisa Lehtiö, Jarmo Kulmala, Vesa Oikonen, Olli Eskola, Jörgen Bergman and Heikki Minn
Journal of Nuclear Medicine December 2002, 43 (12) 1674-1680;
Tuula Tolvanen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaisa Lehtiö
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jarmo Kulmala
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vesa Oikonen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olli Eskola
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jörgen Bergman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heikki Minn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Dynamic imaging protocols used for 18F-FETNIM PET dosimetric study. Protocol 1 was used specifically to measure source organ uptake in thorax and abdomen. Protocols 2 and 3 were used in head and neck cancer patients. Frame rates varied in 3 protocols and are explained in text. Tr = transmission scan.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Activity of 18F-FETNIM in 4 source organs shows clearly higher activity than rest of body: blood, spleen, liver, and kidneys. Solid line is mean curve of individual values. Activity has been normalized to 1-MBq injected dose and 70-kg body weight. Similar shape in curves for blood, liver, and spleen indicates that blood activity has major impact on dose of 2 parenchymal organs.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Activity of 18F-FETNIM in source organs shows relatively low activity: muscle, brain, bone marrow, and lung. Solid line is mean curve of individual values. Activity has been normalized to 1-MBq injected dose and 70-kg body weight.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    18F-FETNIM urine activity. Fitted curve is based on 28 samples from 27 patients. Note high percentage of total injected activity excreted in bladder for subjects holding urine. ID = injected dose.

Tables

  • Figures
    • View popup
    TABLE 1

    Residence Times of 18F-FETNIM

    Source organTime (h)No. of patients
    Brain0.0233
    Stomach0.0092
    Upper large intestine0.0123
    Heart contents0.01120
    Kidneys0.0334
    Liver0.1526
    Lungs0.0157
    Muscle1.0606
    Pancreas0.0062
    Red marrow0.0534
    Spleen0.0136
    Urinary bladder content 2 h0.11027
    Urinary bladder content 4 h0.24427
    Rest of body 2 h0.795
    Rest of body 4 h0.760
    • View popup
    TABLE 2

    Absorbed Doses of 18F-FETNIM to Target Organs

    Target organVoiding interval18F-FMISO* 2 h (mGy/MBq)18F-FDG
    2 h (mGy/MBq)4 h (mGy/MBq)ICRP 60† (mGy/MBq)MIRD 19‡ (mGy/MBq)
    Adrenals0.0120.0120.0170.012
    Brain0.0060.0060.0090.0280.046
    Breasts0.0070.0070.0120.009
    Gallbladder wall0.0140.0140.0150.012
    Lower large intestine wall0.0120.0140.0140.015
    Small intestine0.0120.0120.0110.013
    Stomach0.0120.0120.0130.011
    Upper large intestine wall0.0140.0150.0140.012
    Heart wall0.0110.0110.0190.0620.068
    Kidneys0.0270.0270.0160.0210.021
    Liver0.0240.0240.0180.0110.024
    Lungs0.0080.0080.0100.0100.015
    Muscle0.0120.0120.0140.011
    Ovaries0.0130.0140.0180.0150.011
    Pancreas0.0190.0190.0170.0120.014
    Red marrow0.0120.0120.0100.0110.011
    Bone surfaces0.0110.0110.0080.011
    Skin0.0070.0070.0050.008
    Spleen0.0200.0200.0160.0110.015
    Testes0.0100.0110.0150.0120.011
    Thymus0.0090.0090.0160.011
    Thyroid0.0090.0090.0150.010
    Urinary bladder wall0.0620.1270.0210.1600.073
    Uterus0.0150.0180.0180.0210.012
    Total body0.0110.0110.013
    Effective dose equivalent§0.0170.0210.013
    Effective dose§0.0150.0190.019
    • ↵* Median values from 18F-FMISO dosimetry study (9).

    • ↵† Median values from 18F-FDG ICRP dosimetry (14).

    • ↵‡ Median values from 18F-FDG MIRD 19 dosimetry (20).

    • ↵§ Units are mSv/MBq.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 43, Issue 12
December 1, 2002
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
18F-Fluoroerythronitroimidazole Radiation Dosimetry in Cancer Studies
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
18F-Fluoroerythronitroimidazole Radiation Dosimetry in Cancer Studies
Tuula Tolvanen, Kaisa Lehtiö, Jarmo Kulmala, Vesa Oikonen, Olli Eskola, Jörgen Bergman, Heikki Minn
Journal of Nuclear Medicine Dec 2002, 43 (12) 1674-1680;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
18F-Fluoroerythronitroimidazole Radiation Dosimetry in Cancer Studies
Tuula Tolvanen, Kaisa Lehtiö, Jarmo Kulmala, Vesa Oikonen, Olli Eskola, Jörgen Bergman, Heikki Minn
Journal of Nuclear Medicine Dec 2002, 43 (12) 1674-1680;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • First Evaluation of PET-Based Human Biodistribution and Dosimetry of 18F-FAZA, a Tracer for Imaging Tumor Hypoxia
  • Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 Determined from Whole-Body PET/CT in Monkeys and Humans
  • Google Scholar

More in this TOC Section

  • Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer
  • Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers
  • PET/MRI of Hypoxic Atherosclerosis Using 64Cu-ATSM in a Rabbit Model
Show more Basic Science Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire